FindTrial
Sign In

to check safety of cosmetic products through primary irritation patch tes

Evaluation of Dermatological Safety of Investigational Products by Primary Irritation Patch Test on Healthy Human Volunteers of varied skin types.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/04/012973
Enrollment
24
Registered
2018-04-03
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: 1. Deodorant (4090D) 2. Deodorant (4090E) 3. Deodorant (4090F) 4. Skin Leave-on (GPPCPB535475) 5. Skin Leave-on (CCAST0245LK) 6. Skin Leave-on (AASGTG106025) 7. Skin Leave-on (AASGOG106
the product is leave on products in powdered form So slurry will be prepared in distilled water, it is placed directly in the aluminum chambers and applied on the back of the volunteers at T0 visit 3
the products are leave on products so are placed directly in the aluminum chambers of the patch and applied on the back of the volunteers at T0 visit 4. For products 8 to 10,15,16 & 18 to 20, The pro

Sponsors

ITC Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Skin is healthy on the studied anatomic unit (free of eczema,wounds, inflammatory scarââ?¬Â¦.) Subjects representing varied skin types (ideally equal representation of all 4 skin types ââ?¬â?? Oily, Normal, Dry and combination) Subjects willing to come for regular follow up and ready to follow instructions during the study period

Exclusion criteria

Exclusion criteria: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months, Having refused to give his/her assent by signing the consent form, Taking part in another study liable to interfere with this study Being diabetic,Being asthmatic,Having eczema, oriasis, lichen plan, vitiligo whatever the considered area, Having disorder of the healing (whatever the considered area),Having a rhinitis, allergic conjunctivitis or rhinosinusitis

Design outcomes

Primary

MeasureTime frame
To evaluate the dermatological safety of investigational products by primary irritation patch test on healthy human volunteers of varied skin types Timepoint: T0-baseline, T1-patch removal, T2, T8-follow up—

Secondary

MeasureTime frame
not applicableTimepoint: not applicable—

Countries

India

Contacts

Public ContactMohit Lalvani

MASCOT-SPINCONTROL India Pvt. Ltd.

mohit@mascotspincontrol.in02243349191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026